4D Molecular Therapeutics Inc
(FDMT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -36,146 | -28,313 | -13,160 | -49,306 |
| Depreciation Amortization | 1,072 | 703 | 344 | 1,004 |
| Accounts receivable | 82 | 250 | 99 | N/A |
| Accounts payable and accrued liabilities | -524 | 2,251 | -333 | N/A |
| Other Working Capital | -1,619 | 5,440 | -2,150 | 259 |
| Other Operating Activity | 3,725 | -370 | 1,330 | 11,332 |
| Operating Cash Flow | $-33,410 | $-20,039 | $-13,870 | $-36,711 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -492 | -841 | -721 | -3,203 |
| Investing Cash Flow | $-492 | $-841 | $-721 | $-3,203 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 557 | 5 | 5 | N/A |
| Other Financing Activity | 72,448 | 72,100 | -394 | -2,195 |
| Financing Cash Flow | $73,005 | $72,105 | $-389 | $-2,195 |
| Beginning Cash Position | 49,652 | 49,652 | 49,652 | 91,761 |
| End Cash Position | 88,755 | 100,877 | 34,672 | 49,652 |
| Net Cash Flow | $39,103 | $51,225 | $-14,980 | $-42,109 |
| Free Cash Flow | ||||
| Operating Cash Flow | -33,410 | -20,039 | -13,870 | -36,711 |
| Capital Expenditure | -492 | -841 | -721 | N/A |
| Free Cash Flow | -33,902 | -20,880 | -14,591 | -36,711 |